CEO Gunilla Osswald and CFO Anders Martin-Löf are set to lead the presentation, which will focus on the company's progress in developing treatments for neurodegenerative conditions. The session will include a live Q&A segment for investors, analysts, and media representatives. Participants wishing to submit written queries may do so through the company's webcast portal, while those requiring verbal interaction must register for the teleconference to receive access credentials.

BioArctic, known for its work on the Alzheimer’s drug Leqembi, continues to advance a pipeline that includes antibody treatments for Parkinson’s and ALS. Many of these projects leverage the firm's proprietary BrainTransporter technology, designed to improve drug delivery across the blood-brain barrier. An on-demand recording of the presentation will be archived on the investor relations section of the company’s website following the event.